[go: up one dir, main page]

PT2970980T - Métodos de produção para controlor o teor de lisina c-terminal, galactose e ácido siálico em proteínas recombinantes - Google Patents

Métodos de produção para controlor o teor de lisina c-terminal, galactose e ácido siálico em proteínas recombinantes

Info

Publication number
PT2970980T
PT2970980T PT14768761T PT14768761T PT2970980T PT 2970980 T PT2970980 T PT 2970980T PT 14768761 T PT14768761 T PT 14768761T PT 14768761 T PT14768761 T PT 14768761T PT 2970980 T PT2970980 T PT 2970980T
Authority
PT
Portugal
Prior art keywords
galactose
control
acid content
sialic acid
manufacturing methods
Prior art date
Application number
PT14768761T
Other languages
English (en)
Inventor
Flikweert Marcel
Goochee Charles
Maslanka Francis
Johannes Ignatius Nagel Francisus
Ryland James
Schafer Eugene
Original Assignee
Janssen Biotech Inc
Janssen Biologics B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51528780&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2970980(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Biotech Inc, Janssen Biologics B V filed Critical Janssen Biotech Inc
Publication of PT2970980T publication Critical patent/PT2970980T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
PT14768761T 2013-03-15 2014-03-07 Métodos de produção para controlor o teor de lisina c-terminal, galactose e ácido siálico em proteínas recombinantes PT2970980T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361791094P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
PT2970980T true PT2970980T (pt) 2018-11-19

Family

ID=51528780

Family Applications (1)

Application Number Title Priority Date Filing Date
PT14768761T PT2970980T (pt) 2013-03-15 2014-03-07 Métodos de produção para controlor o teor de lisina c-terminal, galactose e ácido siálico em proteínas recombinantes

Country Status (27)

Country Link
US (3) US20140273092A1 (pt)
EP (1) EP2970980B2 (pt)
JP (1) JP2016512029A (pt)
KR (1) KR102216003B1 (pt)
CN (1) CN105378086B (pt)
AR (2) AR095660A1 (pt)
AU (2) AU2014237635B2 (pt)
BR (1) BR112015022971B1 (pt)
CA (1) CA2907140A1 (pt)
CY (1) CY1120980T1 (pt)
DK (1) DK2970980T3 (pt)
EA (1) EA201591807A1 (pt)
ES (1) ES2690047T3 (pt)
HR (1) HRP20181741T1 (pt)
IL (1) IL240689B (pt)
LT (1) LT2970980T (pt)
MX (1) MX366910B (pt)
PH (1) PH12015501837B1 (pt)
PL (1) PL2970980T3 (pt)
PT (1) PT2970980T (pt)
RS (1) RS57791B1 (pt)
SG (1) SG11201507577RA (pt)
SI (1) SI2970980T1 (pt)
SM (1) SMT201800550T1 (pt)
TW (1) TWI630216B (pt)
WO (1) WO2014149935A1 (pt)
ZA (1) ZA201507671B (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
WO2014143205A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
SMT201800550T1 (it) * 2013-03-15 2019-01-11 Janssen Biotech Inc Metodi di fabbricazione per regolare il contenuto di lisina c-terminale,galattosio e acido sialico in proteine combinanti
CA2915948A1 (en) 2013-08-20 2015-02-26 Lek Pharmaceuticals D.D. Cell culture medium and process for controlling a-amidation and/or c-terminal amino acid cleavage of polypeptides
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
CA3004138A1 (en) 2015-11-03 2017-05-11 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and tim-3 and their uses
JP2018536404A (ja) * 2015-11-09 2018-12-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃｈｏ細胞において産生したポリペプチドの品質特性を操作する方法
MA44072A (fr) 2015-12-17 2018-10-24 Janssen Biotech Inc Anticorps se liant spécifiquement à hla-dr et leurs utilisations
WO2018031400A1 (en) 2016-08-12 2018-02-15 Janssen Biotech, Inc. Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
EP3497120A1 (en) 2016-08-12 2019-06-19 Janssen Biotech, Inc. Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
JP2020522266A (ja) 2017-06-05 2020-07-30 ヤンセン バイオテツク，インコーポレーテツド 非対称なｃｈ２−ｃｈ３領域の変異を有する、操作された多重特異性抗体及び他の多量体タンパク質
CA3065516A1 (en) 2017-06-05 2018-12-13 Janssen Biotech, Inc. Antibodies that specifically bind pd-1 and methods of use
WO2019077628A1 (en) * 2017-10-16 2019-04-25 Council Of Scientific & Industrial Research ZINC SUPPLEMENTATION TO DECREASE GALACTOSYLATION OF RECOMBINANT GLYCOPROTEINS
WO2019224713A2 (en) 2018-05-24 2019-11-28 Janssen Biotech, Inc. Monospecific and multispecific anti-tmeff2 antibodies and there uses
CA3125443A1 (en) * 2018-12-31 2020-07-09 Momenta Pharmaceuticals, Inc. Methods of producing ustekinumab
EP4004057A1 (en) 2019-07-26 2022-06-01 Janssen Biotech, Inc. Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses
CN114258400A (zh) 2019-08-15 2022-03-29 詹森生物科技公司 用于改进的单链可变片段的材料和方法
JOP20220220A1 (ar) 2020-03-13 2023-01-30 Janssen Biotech Inc مواد وطرق لربط لكتين شبيه بالجوبيولين المناعي بحمض سياليك
WO2021240388A1 (en) 2020-05-27 2021-12-02 Janssen Biotech, Inc. Proteins comprising cd3 antigen binding domains and uses thereof
WO2022024024A2 (en) 2020-07-29 2022-02-03 Janssen Biotech, Inc. Proteins comprising hla-g antigen binding domains and their uses
TW202231292A (zh) 2020-10-13 2022-08-16 美商健生生物科技公司 用於調節分化簇ｉｖ及／或ｖｉｉｉ的經生物工程改造之ｔ細胞介導之免疫力、材料、及其他方法
WO2022084915A1 (en) 2020-10-22 2022-04-28 Janssen Biotech, Inc. Proteins comprising delta-like ligand 3 (dll3) antigen binding domains and their uses
AU2022214491A1 (en) 2021-01-28 2023-09-14 Janssen Biotech, Inc. Psma binding proteins and uses thereof
BR112023019464A2 (pt) 2021-03-24 2023-12-05 Janssen Biotech Inc Anticorpo que tem como alvo cd22 e cd79b
MX2023011266A (es) 2021-03-24 2023-12-07 Janssen Biotech Inc Proteínas que comprenden dominios de unión al antígeno de cd3 y usos de estas.
TW202328193A (zh) 2021-09-13 2023-07-16 美商健生生物科技公司 用於治療癌症的CD33 x Vδ2多特異性抗體
WO2023046322A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceutica Nv Proteins comprising cd20 binding domains, and uses thereof
WO2023089587A1 (en) 2021-11-22 2023-05-25 Janssen Biotech, Inc. Compositions comprising enhanced multispecific binding agents for an immune response
WO2024089551A1 (en) 2022-10-25 2024-05-02 Janssen Biotech, Inc. Msln and cd3 binding agents and methods of use thereof
WO2025032510A1 (en) 2023-08-07 2025-02-13 Janssen Biotech, Inc. Stabilized cd3 antigen binding agents and methods of use thereof
WO2025032508A1 (en) 2023-08-07 2025-02-13 Janssen Biotech, Inc. Enpp3 and cd3 binding agents and methods of use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4870163A (en) 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
DE3631229A1 (de) 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
US5075236A (en) 1987-04-24 1991-12-24 Teijin Limited Method of detecting kawasaki disease using anti-tumor necrosis antibody
CA2064915C (en) 1989-08-07 2001-05-29 Deborah A. Rathjen Tumour necrosis factor binding ligands
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
EP1857554A1 (en) 1991-03-18 2007-11-21 New York University Monoclonal and chimeric antibodies specific for human tumor necrosis factor
FR2807767B1 (fr) † 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
CA2450289A1 (en) † 2003-03-20 2005-05-19 Imclone Systems Incorporated Method of producing an antibody to epidermal growth factor receptor
US20040185047A1 (en) 2003-03-21 2004-09-23 Jill Giles-Komar Anti- TNF antibodies, compositions, methods and uses
CN101052708B (zh) † 2004-11-02 2012-08-29 阿雷斯贸易股份有限公司 哺乳动物细胞的无血清细胞培养基
WO2009126564A1 (en) * 2008-04-07 2009-10-15 Bayer Healthcare Llc Methods of recombinant production of glycoproteins
US9631216B2 (en) * 2011-04-29 2017-04-25 Biocon Research Limited Method for reducing heterogeneity of antibodies and a process of producing the antibodies thereof
EP2729561A4 (en) 2011-07-08 2015-06-24 Momenta Pharmaceuticals Inc CELL CULTURE METHOD
US9181572B2 (en) * 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
SMT201800550T1 (it) * 2013-03-15 2019-01-11 Janssen Biotech Inc Metodi di fabbricazione per regolare il contenuto di lisina c-terminale,galattosio e acido sialico in proteine combinanti

Also Published As

Publication number Publication date
IL240689A0 (en) 2015-10-29
US20220089712A1 (en) 2022-03-24
EP2970980A1 (en) 2016-01-20
SG11201507577RA (en) 2015-10-29
US11149085B2 (en) 2021-10-19
MX2015012361A (es) 2016-04-28
AR095660A1 (es) 2015-11-04
LT2970980T (lt) 2018-10-25
IL240689B (en) 2021-12-01
JP2016512029A (ja) 2016-04-25
EA201591807A1 (ru) 2016-02-29
CA2907140A1 (en) 2014-09-25
TW201441263A (zh) 2014-11-01
SI2970980T1 (sl) 2018-11-30
CN105378086B (zh) 2019-05-28
EP2970980B2 (en) 2022-07-27
CN105378086A (zh) 2016-03-02
CY1120980T1 (el) 2019-12-11
PH12015501837A1 (en) 2015-11-09
WO2014149935A1 (en) 2014-09-25
AR124871A2 (es) 2023-05-17
HRP20181741T1 (hr) 2018-12-28
EP2970980B1 (en) 2018-08-15
EP2970980A4 (en) 2016-09-07
AU2014237635A1 (en) 2015-09-03
US20160237149A1 (en) 2016-08-18
AU2020203864A1 (en) 2020-07-02
MX366910B (es) 2019-07-30
PH12015501837B1 (en) 2022-02-11
RS57791B1 (sr) 2018-12-31
ZA201507671B (en) 2017-11-29
KR20150129025A (ko) 2015-11-18
AU2014237635B2 (en) 2020-03-12
PL2970980T3 (pl) 2019-01-31
AU2020203864B2 (en) 2022-05-26
BR112015022971B1 (pt) 2022-05-17
SMT201800550T1 (it) 2019-01-11
BR112015022971A2 (pt) 2017-11-14
DK2970980T3 (en) 2018-10-22
ES2690047T3 (es) 2018-11-19
US20140273092A1 (en) 2014-09-18
TWI630216B (zh) 2018-07-21
KR102216003B1 (ko) 2021-02-16

Similar Documents

Publication Publication Date Title
HRP20181741T1 (hr) Postupci proizvodnje za kontrolu sadržaja c-terminalnog lizina, galaktoze i sijalinske kiseline u rekombiniranim proteinima
WO2014151878A3 (en) Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
ZA201503097B (en) Production of recombinant vaccine in e. coli by enzymatic conjugation
IL279676A (en) Recombinant proteins and therapeutic uses
HK1200489A1 (en) Recombinant human naglu protein and uses thereof naglu
SG11201505195TA (en) Methods For Reducing Aggregate Content In Protein Preparations
HK1223980A1 (zh) 改進的重組多肽生產方法
IN2014DN00161A (pt)
EP2947143A4 (en) RECOMBINANT CELL, AND PROCESS FOR PRODUCING 1,4-BUTANEDIOL
HK1220492A1 (zh) 重組多肽生產
EP3000890A4 (en) Alphaviral vectors and cell lines for producing recombinant proteins
GB201304973D0 (en) Recombinant protein
SG11201600682PA (en) Expression vector for production of recombinant proteins in prokaryotic host cells
HK1220991A1 (zh) 用於增加的重組蛋白產生的製劑和方法
GB201306114D0 (en) Improvements in and relating to the production and control of ions
SG11201404180RA (en) Cho-gmt recombinant protein expression
HK1221742A1 (zh) 用於在原核細胞中重組生產多肽的方法
GB201308120D0 (en) Recombinant protein and method for its production
GB201320209D0 (en) Improvements in or relating to protein Micro-nets
GB201315578D0 (en) Protein delivery to membranes